Harrow, Inc. Accounts Payable
Harrow, Inc. (HROW) had Accounts Payable of $26.27 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-10
- 2026-06-30: Accounts Payable, Current $26.27M.
- 2026-03-31: Accounts Payable, Current $26.13M.
- 2025-12-31: Accounts Payable, Current $35.35M.
- 2025-09-30: Accounts Payable, Current $18.99M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $26.27M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $26.13M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $35.35M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $18.99M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $23.41M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $37.09M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $38.76M 10-K · filed 2026-03-02 |
| 2012-12-31 | $286.69K 10-K · filed 2013-03-18 |
| 2012-03-31 | $256.71K 10-Q · filed 2012-05-10 |
| 2011-12-31 | $218.61K 10-K · filed 2013-03-18 |
| 2011-09-30 | $178.41K 10-Q · filed 2012-02-23 |
| 2011-06-30 | $176.06K 10-Q · filed 2012-02-23 |
| 2010-12-31 | $73.63K 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |